Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Fulcrum Therapeutics, Inc. - Common Stock
(NQ:
FULC
)
8.600
-0.760 (-8.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fulcrum Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
October 14, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
September 25, 2025
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million.
Via
Benzinga
Earnings Scheduled For May 1, 2025
May 01, 2025
Via
Benzinga
Earnings Scheduled For October 29, 2025
October 29, 2025
Via
Benzinga
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
October 29, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 23, 2025
Via
Benzinga
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
October 22, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Present at Upcoming Investor Meetings
August 26, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Small-Cap Stocks: An Undervalued Opportunity in a Cautious Market?
August 21, 2025
In a financial landscape increasingly dominated by the towering valuations of large-cap technology giants, a quieter, yet potentially profound, narrative is unfolding within the small-cap segment of...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
July 30, 2025
Via
Benzinga
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
July 29, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 29, 2025
Via
Benzinga
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
July 29, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
July 29, 2025
Via
Benzinga
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
July 29, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Monday?
July 28, 2025
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via
Chartmill
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
July 28, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
May 29, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
May 29, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 23, 2025
Via
Benzinga
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 08, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
May 01, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Uncovering Potential: Fulcrum Therapeutics's Earnings Preview
April 30, 2025
Via
Benzinga
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
April 24, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today